Diagnostic method for early detection of ovarian cancer via detection of volatile gases in blood plasma
Reference number | |
Coordinator | VOC Diagnostics AB |
Funding from Vinnova | SEK 1 432 734 |
Project duration | April 2023 - November 2024 |
Status | Completed |
Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
Call | Swelife and Medtech4Health - Collaborative projects for better health autumn 2022 |
Important results from the project
The project goals included technical development of an electronic nose prototype, validation tests and data analysis, clinical pre-study, documentation writing for regulatory approval, and attention to the patient perspective. The project delivered remarkable results in agreement with and beyond the planned activities. It also established the foundation for relevant follow-up projects at both national and international level. The goals we set from the start were fully met.
Expected long term effects
As long-term effects of the project, we expect that the obtained results will accelerate our research-to-business path and give all team members increased competence, credibility, and recognition also beyond the Swedish borders, both in Europe and US. Expectations are high in all our areas of expertise: scientific, technological, medical, and business.
Approach and implementation
In agreement with the project plan, we have developed an instrument (e-nose) and method (machine learning models) for accurate and reliable detection of ovarian cancer based on gas emissions from blood plasma. The activities were right, the collaboration worked well, and the project developed mostly as intended. Despite external factors delayed the ethical approval, sample collection, and decisions on the development of the next version prototype, we were able to fulfill the project goals.